# Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)

> **NCT00034853** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 180 (estimated)

## Conditions studied

- Arthritis, Juvenile Rheumatoid

## Interventions

- **DRUG:** meloxicam oral suspension
- **DRUG:** naproxen oral suspension

## Key facts

- **NCT ID:** NCT00034853
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-12
- **Primary completion:** 2003-06
- **Final completion:** —
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2013-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00034853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00034853, "Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00034853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*